JP7611137B2 - 免疫原性アルギナーゼ２ポリペプチド - Google Patents

免疫原性アルギナーゼ２ポリペプチド Download PDF

Info

Publication number
JP7611137B2
JP7611137B2 JP2021526247A JP2021526247A JP7611137B2 JP 7611137 B2 JP7611137 B2 JP 7611137B2 JP 2021526247 A JP2021526247 A JP 2021526247A JP 2021526247 A JP2021526247 A JP 2021526247A JP 7611137 B2 JP7611137 B2 JP 7611137B2
Authority
JP
Japan
Prior art keywords
cells
arg2
polypeptide
arginase
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526247A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020099582A5 (https=
JP2022507373A5 (https=
JP2022507373A (ja
Inventor
ハルド アンデルセン，マッズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2022507373A publication Critical patent/JP2022507373A/ja
Publication of JPWO2020099582A5 publication Critical patent/JPWO2020099582A5/ja
Publication of JP2022507373A5 publication Critical patent/JP2022507373A5/ja
Application granted granted Critical
Publication of JP7611137B2 publication Critical patent/JP7611137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021526247A 2018-11-14 2019-11-14 免疫原性アルギナーゼ２ポリペプチド Active JP7611137B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1818576.9 2018-11-14
GBGB1818576.9A GB201818576D0 (en) 2018-11-14 2018-11-14 Arginase 2 polypeptides
PCT/EP2019/081369 WO2020099582A1 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides

Publications (4)

Publication Number Publication Date
JP2022507373A JP2022507373A (ja) 2022-01-18
JPWO2020099582A5 JPWO2020099582A5 (https=) 2022-08-30
JP2022507373A5 JP2022507373A5 (https=) 2022-08-30
JP7611137B2 true JP7611137B2 (ja) 2025-01-09

Family

ID=64739444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526247A Active JP7611137B2 (ja) 2018-11-14 2019-11-14 免疫原性アルギナーゼ２ポリペプチド

Country Status (11)

Country Link
US (2) US12234288B2 (https=)
EP (1) EP3880225A1 (https=)
JP (1) JP7611137B2 (https=)
KR (1) KR20210093287A (https=)
CN (1) CN113164545B (https=)
AU (1) AU2019378076B2 (https=)
CA (1) CA3118794A1 (https=)
GB (1) GB201818576D0 (https=)
IL (1) IL283133B1 (https=)
SG (1) SG11202104881VA (https=)
WO (1) WO2020099582A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
JP2025508840A (ja) 2022-02-24 2025-04-10 アイオー バイオテック エーピーエス アルギナーゼ２ワクチン

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507301A (ja) 2008-10-31 2012-03-29 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌を処置するための操作されたヒトアルギナーゼの組成物および方法
WO2017149150A1 (en) 2016-03-04 2017-09-08 Io Biotech Aps Combination therapy against cancer
WO2018032020A1 (en) 2016-08-08 2018-02-15 Aeglea Bio Therapeutics, Llc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
WO2018065563A1 (en) 2016-10-07 2018-04-12 Herlev Hospital Immunogenic arginase peptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507301A (ja) 2008-10-31 2012-03-29 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌を処置するための操作されたヒトアルギナーゼの組成物および方法
WO2017149150A1 (en) 2016-03-04 2017-09-08 Io Biotech Aps Combination therapy against cancer
WO2018032020A1 (en) 2016-08-08 2018-02-15 Aeglea Bio Therapeutics, Llc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
WO2018065563A1 (en) 2016-10-07 2018-04-12 Herlev Hospital Immunogenic arginase peptides

Also Published As

Publication number Publication date
CN113164545A (zh) 2021-07-23
AU2019378076B2 (en) 2025-08-07
IL283133A (en) 2021-06-30
GB201818576D0 (en) 2018-12-26
US12234288B2 (en) 2025-02-25
CN113164545B (zh) 2026-04-10
AU2019378076A1 (en) 2021-05-27
CA3118794A1 (en) 2020-05-22
SG11202104881VA (en) 2021-06-29
KR20210093287A (ko) 2021-07-27
EP3880225A1 (en) 2021-09-22
JP2022507373A (ja) 2022-01-18
WO2020099582A1 (en) 2020-05-22
IL283133B1 (en) 2026-03-01
US20210403566A1 (en) 2021-12-30
US20250388674A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
US20250388674A1 (en) Immunogenic arginase 2 polypeptides
AU2020287902B9 (en) TGF-beta vaccine
US20250205318A1 (en) Arginase1 polypeptides
US20250161422A1 (en) Arginase 2 vaccine
AU2023374733A1 (en) Tgf-beta-1 vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241223

R150 Certificate of patent or registration of utility model

Ref document number: 7611137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150